ArticleiScience2026
Challenging the control through a single-cell perspective on normal adjacent tissue in colorectal cancer.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While normal adjacent tissue (NAT) is used as a standard control in cancer studies, NAT in close proximity to the tumor can display tumor-like molecular features, which are associated with a higher risk of local recurrence in colorectal cancer (CRC). To investigate the cellular composition and molecular features of NAT in detail, we analyzed single-cell RNA sequencing and spatial transcriptomics datasets of CRC tissue, corresponding NAT, and healthy colorectal biopsies. Our findings revealed significant differences in both cellular composition and gene expression profiles between healthy, NAT, and tumor tissues. We identified differentially expressed genes between healthy and normal adjacent tissue for each cell type, as well as tumor-associated copy number variations within NAT. Furthermore, we identified gene panels that effectively distinguish between healthy tissue and tissues exhibiting tumor-associated gene expression profiles, including NAT and tumor tissue. Finally, we developed a pharmacological strategy to reverse tumor-associated gene expression patterns
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.